Evaluation of Risk Factors for Laryngeal Squamous Cell Carcinoma: A Single-Center Retrospective Study

Qihe Zhang1,2,3,4†, Huanhuan Wang1,2,3†, Qin Zhao1,2,3, Yuyu Zhang1,2,3, Zhuangzhuang Zheng1,2,3, Shiyu Liu1,2,3, Zijing Liu1,2,3, Lingbin Meng5, Ying Xin4* and Xin Jiang1,2,3*

1 Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China, 2 Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China, 3 NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China, 4 Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China, 5 Department of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL, United States

Background: The survival rate of patients with laryngeal squamous cell carcinoma (LSCC) is correlated with several factors. However, the independent prognostic factors of patients with LSCC remain unclear. Thus, we sought to identify prognostic factors affecting LSCC outcomes in the Chinese population.

Methods: The survival and potential prognostic factors of 211 patients with LSCC between April 2011 and July 2019 were retrospectively analyzed. Overall survival (OS) and progression free survival (PFS) were estimated by the Kaplan Meier method, and a log-rank test was used to compare the possible prognostic factors between different groups. The Cox proportional hazards regression model was used to perform multivariable analysis of significant covariants.

Results: A total of 211 LSCC patients were included, of which 164 (77.7%) were male and 47 (22.3%) were female. Mean age was 62.19 ± 8.328 years. A univariate analysis showed that seven factors including pathological differentiation, clinical stage, tobacco consumption, alcohol consumption, T stage, N stage, and concurrent chemoradiotherapy were correlated with survival (P<0.05). Cox proportional hazards regression analyses revealed that clinic stage (hazard ratio=3.100, p=0.048), pathological differentiation (hazard ratio = 2.538, p=0.015), alcohol consumption (hazard ratio = 8.456, p =0.004) were associated with OS in LSCC. Pathological differentiation (hazard ratio =5.677, p=0.000), alcohol consumption (hazard ratio =6.766, p=0.000) were associated with PFS in LSCC.

Conclusions: Pathological differentiation, alcohol consumption, are independent prognostic factors and predictors of recurrence in LSCC. These factors could help inform guidelines for clinical treatment and prognosis.

Keywords: laryngeal squamous cell carcinoma, prognostic factors, overall survival, progression-free survival, Chinese population
INTRODUCTION

Laryngeal squamous cell carcinoma (LSCC) is the second most common primary malignant tumor of the respiratory tract after lung cancer. It is also the second most common primary epithelial malignant tumor of the head and neck. The age of onset of LSCC is mostly between 50 and 70 years. With a sex ratio of approximately 4:1, most LSCC patients are male (1). According to estimates by the American Cancer Society, in the United States, approximately 12,370 patients will be diagnosed with LSCC and 3750 of them will die from the disease in 2020 (2). Etiology has confirmed that smoking and drinking are related to the occurrence and development of LSCC, and the survival rate of smokers and drinkers is lower than that of non-smokers and non-drinkers (1, 3). Due to the increase in tobacco and alcohol consumption and occupational exposure to toxic substances like polycyclic aromatic hydrocarbons (PAH), the prevalence rate of LSCC has increased in recent years (4, 5).

The factors affecting the prognosis and survival of patients with LSCC can be classified into host, tumor, and treatment factors. The 5-year survival rate for patients with early LSCC is 70 to 90%; while for patients with advanced LSCC, it is only about 30%. Some published studies have stated that younger patients have better survival rates and prognosis than older patients (6, 7), but other studies observed that younger patients have higher risk of recurrence than older patients (8). Sex is another factor related to LSCC prognosis, with females appearing to have better prognosis than males (9). However, this trend may be due to other factors such as the uneven distribution of smoking habits between males and females. Malnutrition has also been identified as an independent prognostic factor of LSCC (10). Further, general condition of the patients, such as the existence of complications, can affect prognosis and survival. For example, pre-treatment hemoglobin levels were also found to be another factor affecting prognosis (11, 12). Regarding the immunological response, immunosuppressed patients seem to have a poor prognosis (13). The site of the primary tumor can also affect prognosis. According to the anatomical position, LSCC can be divided into supraglottic, glottic, and subglottic. In recent years, classification of LSCC as para-glottic LSCC has become controversial and has not been confirmed by the Union for International Cancer Control. Para-glottic LSCC originates in the laryngeal chamber and crosses the supraglottic region and glottic area. Supraglottic cancers have worse prognosis than glottic and subglottic cancers. This could be attributed to the fact that supraglottic cancers have a higher risk of lymph node metastasis (14). Clinical stage is another obvious prognostic factor (9). Increasing T and N stages could lead to higher risk of recurrence and poor prognosis (15). Distant metastases are also associated with poor survival (16). Patients with cervical lymph node metastasis had a worse prognosis than those without lymph node metastasis. Further, compared with highly differentiated LSCC, poorly differentiated LSCC usually has a higher risk of metastases (17). Finally, there are also several biomarkers, such as EGFR (18), WRAP53β, p16INK4a (19), estrogen receptor (ER-β) progestosterone receptor (PR) (20), p53 (21, 22), and Bcl-2 (23) which have been linked with poor prognosis and lower survival rate.

The main treatments for LSCC are surgery, radiotherapy, and chemotherapy. Partial laryngectomy or total laryngectomy is feasible in early cases, and new laryngeal reconstruction is feasible in total or subtotal laryngectomy. Management of LSCC is particularly challenging due to the substantial functional morbidity and psychosocial impact of laryngectomy. Therefore, there is a need to find a balance between optimal tumor control and preserving organ function. While the efficacy of radiotherapy alone for early LSCC is similar to surgical treatment, the physiological function of the larynx can be preserved better by radiotherapy alone. When radiotherapy fails, salvage surgery is feasible. For middle and advanced LSCC, comprehensive treatments such as surgery, radiotherapy, and chemotherapy are the main treatments. Preoperative or postoperative radiotherapy can improve survival rate. The overall survival (OS) and progression free survival (PFS) of patients with negative margins have been shown to be better than those of patients with positive margins (24). The curative effect of surgical treatment has been reported to be better than that of radiotherapy alone (25).

Other factors such as HPV infection can also be pathogenic for LSCC (26). However, whether factors such as sex or age are involved in the prognosis of LSCC remain unclear and require further study (27). We performed a retrospective analysis to investigate the possible prognostic factors of LSCC, including sex, age, tumor location, clinical stage, pathological differentiation, tobacco consumption, and alcohol consumption. Our study could help inform clinical strategies for treatment and improve the survival rate and quality of life of patients.

METHODS

This study included patients with LSCC treated in our hospital from April 2011 to July 2019. The research was approved by the Ethics Committee of the First Bethune Hospital of Jilin University, and all participants provided informed consent. Inclusion criteria were as follows: 1) LSCC was confirmed by pathological diagnosis; 2) complete clinical history and informed consent was provided; 3) complete follow-up data were available; 4) In the early stage of LSCC, radical radiotherapy is performed, and postoperative radiotherapy or concurrent chemoradiotherapy is required. Exclusion criteria: 1) Patients with distant metastasis before treatment; 2) Patients whose histopathological type is not squamous cell carcinoma; 3) Patients who have not completed the treatment plan; 4) Patients without survival data. Patients were staged according to the American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edition (28). We collected information on the following prognostic factors of selected patients: age, sex, smoking, drinking, stage, classification, and pathological differentiation.
Follow-up data which contained survival status, disease progression, recurrence, and death, were collected every 3 months. OS was defined as the time from the date of diagnosis to the date of death. PFS was defined as the time from diagnosis to disease progression or death (if no progression was reported before death) or the date of last follow-up. Recurrence was classified as local, regional, and distant metastasis.

Statistical analysis was performed using SPSS 26.0 (SPSS Inc., Chicago IL, USA). Quantitative data were presented as mean ± SD while qualitative data were presented by rate. The overall survival rate (OS) and progression-free survival rate (PFS) were estimated by Kaplan-Meier curve. Kaplan-Meier curves were compared according to age, sex, smoking, drinking, staging, classification, pathological differentiation and simultaneous radiotherapy and chemotherapy. The independent factors affecting mortality and progression (recurrence and metastasis) without metastasis were evaluated by Cox proportional hazard ratio model. The significant factors observed in the univariate Cox proportional hazard ratio model were gradually incorporated into the multivariate Cox proportional hazard ratio model, except that T period and N period were excluded because of multiple collinearity, the other factors gradually entered the multivariate Cox proportional risk ratio model. All statistical tests were two-sided. Differences were considered statistically significant at P values < 0.05.

### Baseline Characteristics

For the duration of the study, we included patients admitted to our hospital from April 2011 to July 2019 and according to the exclusion criteria. Patient characteristics are shown in Table 1. Patients included 164 males (77.7%) and 47 females (22.3%), and mean age was 62.19 years (range 41–87). There were 167 patients (79.1%) with a history of tobacco consumption, while 141 of the patients (66.8%) had a history of alcohol consumption. Types of LSCC included supra-glottic (50.2%), glottic (43.6%), sub-glottic (2.4%), and para-glottic (3.8%). Most patients were stage T2 + T1 (71.1%), 28.9% were T3 + T4. More than a half of the patients (59.7%) were in N0 stage, 11.8% were in N1, 27.5% in N2, and 0.9% in N3. Nearly 30% of patients were at clinical stage I (26.1%), and more than 30% were at clinical stage IV (35.1%). Meanwhile, 20.9% and 79.1% of patients had low or high pathological differentiation, respectively. Most patients (63.5%) were treated with surgery and radiotherapy 67 patients (31.8%) were accepted radiotherapy and surgery plus chemotherapy, while patients treated with radiotherapy only and radiotherapy plus chemotherapy were 2.4% and 2.4%, respectively.

### Overall Survival and Prognosis Factors of LSCC

The median follow-up period was 48 months. The 1, 3, and 5-year OS rates were 95.2%, 85.9%, and 83.5%, respectively. The univariate analysis demonstrated that seven factors, including pathological differentiation, clinical stage, tobacco consumption, alcohol consumption, T stage, N stage, and concurrent chemoradiotherapy were significantly associated with survival (P<0.05) (Table 2, Figure 1). The Kaplan Meier survival curves showed that patients with high pathological differentiation had a more favorable prognosis than those with lower pathological differentiation. The 1, 3, and 5-year OS rates of low and high pathological differentiation were 88.4%, 69.2%, and 65.3% and 97%, 90.3%, and 88.4%, respectively. For patients with clinical stage I, the 1, 3, and 5-year OS rates were 100%, 93.5%, and 93.5% respectively, which were better than those with stage II, III and IV. We combined the groups with stage T1 and T2 in order to compare survival status with a group containing patients with T3 and T4 stages. For the T1 and T2 group, the 1, 3, and 5-year OS rates were 96.0%, 88.7%, and 88.7%, respectively, while for the T3 and T4 group they were 93.4%, 79.5%, and 71.9%, respectively.

We also merged stages N2, N3 and compared them with stage N0, N1. The 1, 3, and 5-year survival rates of the N2 and N3 group were 84.9%, 71.1%, and 68.0%, respectively and that of N0 and N1 were 99.3%, 91.6%, and 89.5%, respectively. The 1, 3, and 5-year OS rates of concurrent chemoradiotherapy and radiotherapy only were 94.4%, 78.8%, and 70.9% and 95.6%, 89.5%, and 89.5%, respectively. The 1, 3, and 5-year OS rates of smokers were 94.0%, 84.2%, and 78.8% and 95.6%, 89.5%, and 86.6%, respectively.

### Table 1 | Summary of baseline characteristics.

| Type                  | Frequency | Percent/Mean ± SD |
|-----------------------|-----------|-------------------|
| Sex                   | Male      | 164 (77.7%)       |
|                       | Female    | 47 (22.3%)        |
| Age                   | Mean ± SD | 62.19 ± 8.328     |
| Tobacco               | Yes       | 167 (79.1%)       |
|                       | No        | 44 (20.9%)        |
| Alcohol               | Yes       | 141 (66.8%)       |
|                       | No        | 70 (33.2%)        |
| Type                  | supra-glottic | 106 (50.2%)   |
|                       | glottis   | 92 (43.6%)        |
|                       | sub-glottis | 5 (2.4%)        |
|                       | para-glottic | 8 (3.8%)        |
| Clinic stage          | I         | 55 (26.1%)        |
|                       | II        | 48 (22.7%)        |
|                       | III       | 34 (16.1%)        |
|                       | IV        | 74 (35.1%)        |
| T stage               | T1+ T2    | 150 (71.1%)       |
|                       | T3+ T4    | 61 (28.9%)        |
| N stage               | N0+ N1    | 151 (71.6%)       |
|                       | N2+ N3    | 60 (28.4%)        |
| pathological differentiation | High | 167 (79.1%)       |
|                       | Low       | 44 (20.9%)        |
| concurrent chemoradiotherapy | Yes | 72 (34.1%)        |
|                       | No        | 139 (65.9%)       |
TABLE 2 | Survival rates and univariable analysis of Kaplan-Meier.

| Sex      | Survival rate (%) | Log Rank | P value |
|----------|-------------------|----------|---------|
|          | 1 year | 3 year | 5 year | (x^2) |        |
| Male     | 95.1    | 85.2   | 82.2   | 0.773 | 0.379  |
| Female   | 95.6    | 88.0   | 88.0   |        |        |
| Age      |         |        |        | 5.371 | 0.068  |
| <59      | 94.2    | 82.1   | 76.8   |        |        |
| 60-74    | 96.1    | 89.6   | 88.3   |        |        |
| >75      | 91.7    | 66.7   | 66.7   |        |        |
| Tobacco  |         |        |        | 7.773 | 0.005  |
| Yes      | 94.0    | 82.8   | 79.9   |        |        |
| No       | 100     | 100    | 100    |        |        |
| Alcohol  |         |        |        | 1.197 | 0.001  |
| Yes      | 92.6    | 80.6   | 77.1   |        |        |
| No       | 98.6    | 97.0   | 97.0   |        |        |
| Type     |         |        |        | 1.715 | 0.634  |
| supra-glottic | 93.3 | 83.1 | 81.5 |        |        |
| glottic  | 96.7    | 88.8   | 85.2   |        |        |
| sub-glottic | 100    | 75.0   | 75.0   |        |        |
| para-glottic | 100  | 100    | 100    |        |        |
| Clinic stage |         |        |        | 16.507| 0.001  |
| I        | 100     | 93.5   | 93.5   |        |        |
| II       | 100     | 95.0   | 95.0   |        |        |
| III      | 100     | 90.2   | 82.6   |        |        |
| IV       | 86.4    | 72.5   | 70.2   |        |        |
| T stage  |         |        |        | 5.677 | 0.017  |
| T1/T2   | 96.0    | 88.7   | 88.7   |        |        |
| T3/T4   | 93.4    | 79.5   | 71.9   |        |        |
| N stage  |         |        |        | 12.025| 0.001  |
| N0/N1   | 99.3    | 91.6   | 89.5   |        |        |
| N2/N3   | 84.9    | 71.1   | 68.0   |        |        |
| Pathological differentiation |         |        |        | 13.943| 0.000  |
| Low     | 88.4    | 69.2   | 65.3   |        |        |
| High    | 97.0    | 90.3   | 88.4   |        |        |
| Concurrent chemoradiotherapy |         |        |        | 7.505 | 0.006  |
| Yes     | 94.4    | 78.8   | 70.9   |        |        |
| No      | 95.6    | 89.5   | 89.5   |        |        |

Factors Influencing PFS

From the 211 patients, seven patients were excluded because they died within a short period of time after admission, and therefore, PFS was not analyzed for them. Thus, we investigated the factors influencing PFS for the remaining 204 patients. The 1, 3, and 5-year PFS rate were 96.5%, 84.0%, 73.6%, respectively. The univariate analysis of PFS rendered similar results to those of OS. Seven factors, including pathological differentiation, clinical stage, tobacco consumption, alcohol consumption, T stage, and N stage, and concurrent chemoradiotherapy were significantly correlated with recurrence (P<0.05) (Figure 2). The Kaplan Meier survival analysis showed that patients with high pathological differentiation are more likely to have recurrence than patients with low pathological differentiation (P<0.05).

For patients with clinical stage I, the 1, 3, 5-year recurrence rates were 1.8%, 5.5%, 9.1%, respectively, which were better than those of patients with stage II, III and IV (P=0.000). For T1/2 group, the 1, 3, and 5-year PFS rates were 97.9%, 88.2%, and 78.1%, respectively, while for the T3/4 group the rates were 93.2%, 73.5%, and 62.0%, respectively.

The 1, 3, and 5-year PFS rates of the tobacco consumption group were 96.2%, 80.8%, and 69.1%, respectively, which were higher than the rates of the non-smoking group (P=0.008). Similar to the tobacco consumption group, the alcohol consumption group also had higher risk of recurrence than the non-drinking group (P=0.000). Thus, the 1, 3, and 5-year PFS rates were 96.9%, 78.1%, and 63.1% in the alcohol consumption group, respectively, and 95.7%, 95.7%, and 93.1% in non-drinking group, respectively.

It is generally believed that the N2/3 group is more likely to relapse than the N0/1 group, an idea which was confirmed by our data (P=0.000). The 1, 3, and 5-year PFS rates of the N0/1 group were 97.9%, 88.2%, and 80.9%, respectively, while those of the N2 and N3 group were 92.4%, 70.8%, and 51.6%, respectively.

The 1-, 3- and 5-year survival rates of patients undergoing concurrent chemoradiotherapy and radiotherapy alone were 92.8%, 73.4%, 59.8%, and 98.5%, 89.9%, 80.4%, respectively (Table 4). We then performed a subtype analysis of concurrent chemoradiotherapy based on clinical stage in order to investigate whether the treatment decisions based on clinical staging affect recurrence. The results showed that, although there are no significant differences between all subtypes, the Kaplan Meier survival curve for patients with clinical stage IV showed that concurrent chemoradiotherapy led to a higher tendency of recurrence than radiotherapy only.

Next, we performed a Cox regression analysis to analyze the factors which reached statistical significance in the univariate analysis. Because of multicollinearity, T and N stages were excluded, and concurrent chemoradiotherapy was also excluded because it is not in line with real clinical practices. Smoking, drinking, clinical stages, and differentiation were gradually introduced into the multivariate Cox proportional hazard model through the forward LR method. The Cox regression analysis showed that pathological differentiation, alcohol consumption are independent disease progression factors of LSCC (Table 5). Those with low pathological...
(A) Kaplan-Meier curves for overall survival rate.

(B) There was no significant differences between male and female, p>0.05.

(C) There was no significant differences among age group, p>0.05.

(D) The survival rate for tobacco users was significantly lower than non-smokers, p=0.005.

(E) The survival rate for those who used to drink was significantly lower than those did not, p=0.001.

(F) There was no significant difference among group of type, p>0.05.

(G) The survival rate for those with low pathological differentiation tumors was significantly lower than those were high, p=0.000.

(H) The survival rate for patients with clinical stage IV was significantly lower than those with I, II, III, respectively, p=0.001.

(I) The survival rate for those at stage T3 and T4 was significantly lower than those at T1 and T2, p=0.017.

(J) The survival rate for those at stage N2 and N3 was significantly lower than those at N1 and N0, p=0.05.

(K) The survival rate for those with concurrent chemoradiotherapy was significantly lower than those not, p<0.05.
that younger patients had better survival than older patients (6, factor affecting the survival. In the past, most scholars believed number of female smokers. In addition, age is also a prognostic decreasing smoking rate among male patients and the increasing patients were middle-aged and elderly patients, with an average LSCC patients in different age groups. In this study, most of the observed. The results did not show the differences in survival of patients in different age groups were divided into three groups according to their age groups, and the undifferentiated, with higher rates of recurrence and metastasis, patients have less differentiated tumors, usually poorly or younger patients. However, it has also been found that younger differentiation had higher risk than those with high pathological differentiation (hazard ratios of 5.677, p=0.000). Compared with non-alcohol users, alcohol consumers had a higher risk, with a hazard ratio of 6.766, p=0.000.

**DISCUSSION**

The prognosis of LSCC can be predicted by multiple factors, which can be divided into host, tumor, and treatment factors. In this study we assessed the influence of the above risk factors for the prognosis and recurrence of patients with LSCC. We report a 5-year OS and PFS of 83.5% and 73.6%, respectively, which are better than those reported in the literature (24). This could be due to improved diagnostic methods and better treatment. Otherwise, given that most of our patients had early stage LSCC, this could be attributed to an improvement in patients’ health awareness and the application of multiple examination methods (fiber laryngoscope, electronic laryngoscope, etc.)

Many factors have been reported to affect the prognosis of LSCC patients, such as age, race, smoking and so on. Sex has also been reported to be a prognostic factor for LSCC patients, and the prognosis of female patients is significantly better than that of male patients (9). But the conclusions from different studies are controversial. The univariate analysis results of this study showed that there was no statistical difference in the effect of gender on OS and PFS of LSCC patients. This is consistent with the findings of Walasek et al. (29). This may be related to the decreasing smoking rate among male patients and the increasing number of female smokers. In addition, age is also a prognostic factor affecting the survival. In the past, most scholars believed that younger patients had better survival than older patients (6, 8). This may be related to the better physical condition of the younger patients. However, it has also been found that younger patients have less differentiated tumors, usually poorly or undifferentiated, with higher rates of recurrence and metastasis, which may lead to lower survival rates. In this study, patients were divided into three groups according to their age groups, and the differences in OS and PFS of patients in different age groups were observed. The results did not show the differences in survival of LSCC patients in different age groups. In this study, most of the patients were middle-aged and elderly patients, with an average age of 62.19 years old. The age gap between the patients was relatively small, which may be the reason for this result.

Notably, unhealthy living habits also affect the occurrence, progression, and prognosis of LSCC. There is evidence that greater cigarettes and alcohol consumption have an impact on the incidence and prognosis of LSCC (30, 31). However, other studies have shown different results. For example, Zhang et al. (24) showed that smoking and drinking have no effect on OS and PFS of LSCC. In our study, 167 (79.1%) patients had a history of tobacco consumption and 141 patients (66.8%) had a history of alcohol consumption. The univariate analysis showed that tobacco and alcohol are linked with recurrence and survival, and alcohol is an independent risk factor for OS and PFS. These results are consistent with the existing literature (3, 32). This suggests that smoking and drinking are important reasons for the poor prognosis of LSCC patients after radiotherapy, and lifestyle changes may become an important way to prevent the occurrence of LSCC and improve the prognosis. According to the SEER data, the 5-year survival rate of patients with LSCC varies according to the location of the primary tumor. For example, the 5-year survival rate of glottic cancer is higher than that of supraglottic cancer (6). Patients with supraglottic carcinoma have a higher recurrence rate, which may be related to their susceptibility to lymph node metastasis (8). Although the data showed that supraglottic carcinoma did not cause poor prognosis, the effect of anatomical location on LSCC should not be ignored. Consistently, no differences in survival rates were found among patients with tumors at different anatomic sites in the center. However, we observed that patients with glottic cancer had a more favorable clinical stage than patients with supraglottic cancer. As recommended by the guidelines, we have adopted a more aggressive treatment strategy for patients with supraglottic cancer. Better tumor control associated with intensive treatment may account for a similar prognosis in patients with glottic cancer. According to a multi-center study within the International Head and Neck Cancer Epidemiology (INHANCE) consortium, tumor stage is a positive predictor of cancer recurrence in HNC patients (33). Patients with advanced LSCC have an unfavorable prognosis (34). Most of our patients were stage IV (35.1%), and their 5-year OS and PFS were 70.2% and 52.1%, respectively. Although the univariate analysis showed that both OS and PFS of patients at stage IV were much lower than those of patients at other stages, after excluding T and N stages, the multivariate Cox regression analysis showed that clinical stage was an independent risk factor for survival while it was not an independent risk factor for recurrence of LSCC. Extensive evidence shows that tumor size and lymph node metastasis are important factors affecting the survival and recurrence rates of patients with LSCC (35). In a Danish study of 5001 people, Nina et al. (15) found that increased T stage was a risk factor for recurrence of glottic cancer. Johansen et al. (9) obtained a similar result, and showed that T stage and N stage have a significant effect on the prognosis of LSCC. In our study, T stage was an prognostic factor in the univariate analyses. We combined T1 and T2 groups and compared them with T3 and T4 groups. Univariate analysis showed that group T1/2 have a better

### TABLE 3 | Multivariable Cox proportional hazard models of mortality.

| Covariate | HR (95% CI) | P value |
|-----------|------------|---------|
| Alcohol   |            |         |
| Yes       | 8.456 (2.013, 35.512) | 0.004 |
| No        | –          |         |
| Clinic stage |          |         |
| I         | –          |         |
| II        | 0.541 (0.099, 2.965) | 0.479 |
| III       | 1.759 (0.468, 6.606) | 0.403 |
| IV        | 3.100 (1.009, 9.528) | 0.048 |
| Differentiation |      |         |
| Low       | 2.538 (1.197, 5.381) | 0.015 |
| High      | –          |         |
FIGURE 2 | Kaplan-Meier curves of progression free survival (PFS) probability against time. (A) Kaplan-Meier curves for PFS. (B) There was no significant differences between male and female, p>0.05. (C) There was no significant differences among age group, p>0.05. (D) The PFS rate for tabacoo users was significantly lower than non-smokers, p=0.008. (E) The PFS rate for those who used to drink was significantly lower than those did not, p=0.000. (F) There was no significant difference among group of type, p>0.05. (G) The PFS rate for those with low pathological differentiation tumors was significantly lower than those were high, p=0.000. (H) The PFS rate for patients with clinical stage IV was significantly lower than those with I, II, III, respectively, p=0.000. (I) The PFS rate for those at stage T3 and T4 was significantly lower than those at T1 and T2, p=0.024. (J) The PFS rate for those at stage N2 and N3 was significantly lower than those at N1 and N0, p<0.05. (K) The PFS rate for those with concurrent chemoradiotherapy was significantly lower than those not, p<0.05.
TABLE 4 | Progression free survival rates and univariable analysis of Kaplan-Meier.

| Survival rate (%) | Log Rank (χ²) | P value |
|-------------------|--------------|---------|
|                  | 1 year | 3 year | 5 year |
| Sex               |         |         |        |
| Male              | 97.4   | 82.5   | 71.2   |
| Female            | 93.5   | 88.8   | 81.2   |
| Age               | 1.092  | 0.296  |        |
| <59               | 95.4   | 78.5   | 67.0   |
| 60–74             | 98.4   | 88.3   | 76.9   |
| 75+               | 84.4   | 67.5   | 67.5   |
| Tobacco           | 4.389  | 0.111  |        |
| Yes               | 96.2   | 80.8   | 69.1   |
| No                | 97.7   | 97.7   | 93.1   |
| Alcohol           | 6.968  | 0.008  |        |
| Yes               | 96.9   | 78.1   | 63.1   |
| No                | 95.7   | 95.7   | 91.1   |
| Type              | 6.616  | 0.085  |        |
| supra-glottic     | 95.0   | 79.0   | 64.7   |
| glottis           | 97.7   | 89.0   | 82.1   |
| sub-glottis       | 100    | 80.0   | 80.0   |
| para-glottic      | 100    | 100    | 100    |
| Clinic stage      | 18.619 | 0.000  |        |
| I                 | 98.1   | 94.2   | 86.6   |
| II                | 100    | 92.8   | 84.5   |
| III               | 100    | 84.1   | 80.3   |
| IV                | 91.0   | 68.9   | 52.1   |
| T stage           | 5.131  | 0.024  |        |
| T1+T2             | 97.9   | 88.2   | 78.1   |
| T3+T4             | 93.2   | 73.5   | 62.0   |
| N stage           | 12.157 | 0.000  |        |
| N0+N1             | 97.9   | 88.2   | 80.9   |
| N2+N3             | 92.4   | 70.8   | 51.6   |
| Pathological differentiation | 32.941 | 0.000 |        |
| Low               | 87.9   | 62.9   | 42.3   |
| High              | 98.7   | 89.4   | 82.2   |
| Concurrent chemoradiotherapy | 10.895 | 0.001 |        |
| Yes               | 92.8   | 72.4   | 59.8   |
| No                | 98.5   | 89.9   | 80.4   |

**Due to the limitation of our retrospective analysis, the 5 years survival rate of female, 75+, No tobacco history, Low pathological differentiation, stage I, and II cannot be reached.**

**The survival rate of group sub-glottis, para-glottic cannot be reached for limited sample size.**

prognosis than group T3/4, with 5 years OS and PFS of 88.7% and 78.1%, respectively. Regarding N stage, we merged the N0 stage and N1 stage into one group in order to compare the survival and recurrence with that of group N2 and N3. We observed that N stage has the same effect as T stage on OS and PFS. T and N stages seem to have become a recognized factor affecting prognosis (36). The results of this study were basically similar to the previous mainstream theories, which reflected the consistency of the influence for tumor stage on prognosis in different countries and regions. Though it is generally accepted that distant metastasis could cause unfavorable prognosis (16), the effect of M stage on prognosis could not be elucidated in this study because all patients were in stage M0.

The degree of tumor differentiation is linked with the survival and recurrence rate of patients with LSCC, with poorly differentiated cancers usually having a higher rate of metastatic disease compared with well-differentiated cancers (17). In this study, we merged the moderate- and well- differentiated cases of LSCC into one group and compared it with the group of poorly differentiated LSCC. Results showed that those with poorly differentiated LSCC had an unfavorable prognosis and higher recurrence rate in the univariate analysis. Moreover, the multivariate analysis demonstrated that differentiation is also an independent risk factor for survival and recurrence rate. Our results are consistent with the conclusion of Zhu et al. (37). However, the limitation of this study is that we were unable to assess the impact of moderate differentiation on the prognosis and recurrence of LSCC. In view of the effect of tumor differentiation on patient prognosis, the use of tumor stage alone as a criterion for treatment selection seems to be limited. The toxicity of more intensive treatment to highly differentiated tumors should be concerned. Our study provides a reference for the treatment of patients with highly differentiated tumors, suggesting that the degree of tumor differentiation should also be a reference factor for treatment selection. In order to avoid unnecessary injury caused by overtreatment, it may be possible to treat highly differentiated tumors by downgraded treatment. In addition, the choice of treatment may also be one of the reasons that affect the prognosis of patients. In a randomized controlled trial of 547 patients, Forastiere et al. (25) found no difference in survival between the radiotherapy alone group and the concurrent chemoradiotherapy group. Most of our patients (95.3%) accepted surgery either with concurrent chemoradiotherapy or without it, which might be the reason behind the high survival rate reported in our study. The univariate analysis showed that patients with concurrent chemoradiotherapy have more unfavorable prognosis and shorter PFS, which seems to contradict logic and is also in disagreement with the existing literature. However, according to the guidelines, concurrent chemoradiotherapy is recommended only for patients with advanced tumors. Therefore, the difference in baseline of patients in different treatment groups may be the reason for the different prognosis. Of course, the high adverse reactions of concurrent chemoradiotherapy should not be ignored, and it is urgent to develop drugs with less side effects.

Due to the retrospective design and small sample size of this study, our data did not include surgical margins, occupational exposure, or HPV infection. Therefore, we could not measure the impact of these factors on the incidence and prognosis of LSCC. However, we did analyze other factors that may affect the survival and recurrence rate of patients with LSCC, including patient, clinical and treatment factors. In this study we identified alcohol consumption and pathological differentiation as independent predictors of OS for LSCC. Alcohol consumption, pathological differentiation and clinic stage were identified as independent predictors for OS. Patients with a history of alcohol consumption had a shorter OS compared with non-drinkers. Patients with high pathological differentiation also had a significantly shorter OS compared with patients with low pathological differentiation. The protective effect of smoking history on OS was not observed in our study. In contrast to other studies, our findings suggest that there is no significant association between smoking history and OS in LSCC patients. A possible explanation for this finding is that smoking may not be an important factor in the development and progression of LSCC in our population. A previous study conducted in China found that smoking was positively correlated with the risk of LSCC (38). Another possible explanation for the negative association between smoking history and OS is that smoking may be a marker of other unhealthy behaviors, such as poor diet or limited physical activity, which could contribute to the risk of LSCC in this population. Future studies are needed to further investigate the association between smoking history and OS in LSCC patients.
consumption and poor differentiation had a lower survival rate and were more prone to recurrence. There was no significant difference in OS and PFS between patients with concurrent radiotherapy and patients with radiotherapy alone, suggesting the importance of downgrading therapy in LSCC patients. In order to improve the survival rates of patients with LSCC, the importance of pathological differentiation, alcohol consumption and clinic stage on prognosis must be emphasized in the context of diagnosis and treatment.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article suplementary materials. Further inquiries can be directed to the corresponding authors.

**AUTHOR CONTRIBUTIONS**

Conceptualization, XJ and YX; software, investigation, HHW, QHZ, ZZZ, QZ; resources, YYZ; writing—original draft preparation, HHW, QHZ, QZ, SYL, ZJL; writing—review and editing, LBM, YX, and XJ; funding acquisition, XJ. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Talamini R, Bosetti C, La Vecchia C, Dal Maso L, Levi F, Bidoli E, et al. Combined effect of tobacco and alcohol on laryngeal cancer risk: a case-control study. Cancer Causes Control (2002) 13:957–64. doi: 10.1023/A:1021944123914
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin (2020) 70:7–30. doi: 10.3332/caac.21590
3. La Vecchia C, Zhang ZF, Altieri A. Alcohol and laryngeal cancer: an update. Eur J Cancer Prev (2008) 17:116–24. doi: 10.1097/CEJ.0b013e3282f64d40
4. McMichael AJ. Laryngeal cancer and consumption of alcohol and tobacco. Lancet (1978) 2:1099–100. doi: 10.1016/S0140-6736(78)91835-4
5. Wagner M, Bolm-Audorff U, Hegewald J, Fishta A, Schlattmann P, Schmitt J, et al. Occupational polycyclic aromatic hydrocarbon exposure and risk of larynx cancer: a systematic review and meta-analysis. Occup Environ Med (2015) 72:226–33. doi: 10.1136/oemed-2014-102317
6. Misono S, Marmor S, Yuezh B, Virnig BA. Treatment and survival in 10,429 patients with localized laryngeal cancer: a population-based analysis. Cancer (2014) 120:1810–7. doi: 10.1002/cncr.28608
7. Lacy PD, Piccirillo JF, Merritt MG, Zequeira MR. Head and neck squamous cell carcinoma: better to be young. Otolaryngol Head Neck Surg (2000) 122:253–8. doi: 10.1016/S0194-5998(00)70249-X
8. Brandstorp-Boesen J, Serum Falk R, Folkevand Evensen J, Boysen M, Brondbo K. Risk of Recurrence in Laryngeal Cancer. PloS One (2016) 11:e0164068. doi: 10.1371/journal.pone.0164068
9. Johansen LV, Grau C, Overgaard J. Laryngeal carcinoma—multivariate analysis of prognostic factors in 1252 consecutive patients treated with primary radiotherapy. Acta Oncol (Stockholm Sweden) (2003) 42:771–8. doi: 10.1080/0284186031017595
10. Li ZQ, Zou I, Liu TR, Yang AK. Prognostic value of body mass index before treatment for laryngeal squamous cell carcinoma. Cancer Biol Med (2015) 12:394–400. doi: 10.7497/j.issn.2095-3941.2015.0043
11. Boje CR, Dalton SO, Grienbog TK, Primdahl H, Kristensen CA, Andersen E, et al. The impact of comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database. Acta Oncol (2013) 52:285–93. doi: 10.3109/0284186X.2012.742964
12. Sabin SL, Rosenberg RM, Sundaram K, Har-el G, Lucente FE. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J (1999) 78:578, 581–587, 584. doi: 10.1177/014556139907800813
13. Rabinovics N, Mizrahi A, Hadar T, Ad-El D, Feinmesser R, Guttman D, et al. Cancer of the head and neck region in solid organ transplant recipients. Head Neck (2014) 36:181–6. doi: 10.1002/hed.23283
14. Reid BC, Alberg AJ, Klassen AC, Samet JM, Rozier RG, Garcia I, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer (2001) 92:2109–16. doi: 10.1002/1097-0142(20011015)92:8<2109::AID-CNCR1552>3.0.CO;2-M
15. Lyhne NM, Johansen J, Kristensen CA, Andersen E, Primdahl H, Andersen LJ, et al. Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group. Radiother Oncol (2016) 118:257–66. doi: 10.1016/j.radonc.2016.02.006
16. Silvestri F, Bussani R, Stanta G, Cosati C, Ferlito A. Supraglottic versus glottic laryngeal cancer: epidemiological and pathological aspects. ORL J Otorhinolaryngol Relat Spec (1992) 54:43–8. doi: 10.1159/000276258
17. Devaney KO, Hunter BC, Ferlito A, Rinaldo A. Pretreatment pathological factors in prognostic head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol (1997) 106:983–8. doi: 10.1177/000348499701061117
18. Demiral AN, Sarigolu S, Bilirk B, Sen M, Kinay M. Prognostic significance of EGFR receptor expression in early glottic cancer. Auris Nasus Larynx (2004) 31:47–24. doi: 10.1016/j.anl.2004.05.003
19. Tiefenböck-Hansson K, Haapaniemi A, Farnebo L, Palmgren B, Tarkkanen J, Farnebo M, et al. WRAF538, survivin and p16INK4a expression as potential predictors of radiotherapy/chemoradiotherapy response in T2N0–T3N0 glottic laryngeal cancer. Oncol Rep (2017) 38:2062–8. doi: 10.3892/or.2017.5898
20. Atef A, El-Rashidy MA, Elzayat S, Kabel AM. The prognostic value of sex hormone receptors expression in laryngeal carcinoma. Tissue Cell (2019) 57:84–9. doi: 10.1016/j.tice.2019.02.007
21. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 333:249–345. doi: 10.1056/NEJM199502163330704
22. Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med (2000) 29:413–25. doi: 10.1034/j.1600-0714.2000.290901.x

**FUNDING**

This work was supported by the National Natural Science Foundation of China (grant number 81570344), National Key R&D Program of China (grant number 2017YFC0112100), the Education Department Foundation of Jilin Province (grant number JJKH20201036J), the Health and Family Planning Commission of Jilin Province Foundations (grant number 2016Q034 and 2017J11), the Fundamental Research Funds for the Central Universities of Jilin University, and the Jilin Provincial Science and Technology Foundations (grant number 20180414039GH and 20190201200JC).

**ACKNOWLEDGMENTS**

We would like to thank Editage (www.editage.cn) for English language editing.
23. Georgiou A, Gomatos IP, Ferekidis E, Syrigos K, Bistola V, Giotakis J, et al. Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma. *Eur J Surg Oncol* (2001) 27:574–80. doi: 10.1053/ejso.2001.1131

24. Zhang S-Y, Lu Z-M, Luo X-N, Chen L-S, Ge P-J, Song X-H, et al. Retrospective analysis of prognostic factors in 205 patients with laryngeal squamous cell carcinoma who underwent surgical treatment. *PloS One* (2013) 8:e60157. doi: 10.1371/journal.pone.0060157

25. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* (2003) 349:2091–8. doi: 10.1056/NEJMoa031317

26. Bates JE, Morris CG, Hitchcock KE, Dziegielewski PT, Mendenhall WM, Amdur RJ. Locally advanced hypopharyngeal and laryngeal cancer: Influence of HPV status. *Radiother Oncol* (2019) 140:6–9. doi: 10.1016/j.radonc.2019.05.013

27. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. *Laryngoscope* (2006) 116:1–13. doi: 10.1097/01.mlg.0000236095.97947.26

28. Brierley JD, Gospodarowicz MK, Wittekind C. *TNM classification of malignant tumours*. New Jersey: John Wiley & Sons (2017) 25(8):1483–1491.

29. Walasek T, Dymek P, Kowalska T, Reinfuss M. [Is gender a prognostic factor in early stages of laryngeal cancer treated by radiotherapy?]. *Otolaryngol Pol* (1997) 60:32–40. doi: 10.1007/s10654-018-0409-5

30. Pantel M, Guntinas-Lichius O. [Laryngeal carcinoma: epidemiology, risk factors and survival]. *HNO* (2012) 60:32–40. doi: 10.1007/s00106-011-2423-8

31. Lubin JH, Gaudet MM, Olshan AF, Kelsey K, Boffetta P, Brennan P, et al. Body mass index, cigarette smoking, and alcohol consumption and cancers of the oral cavity, pharynx, and larynx: modeling odds ratios in pooled case-control data. *Am J Epidemiol* (2010) 171:1250–61. doi: 10.1093/aje/kwp088

32. Papadas TA, Alexopoulos EC, Malisis A, Jelastopulu E, Mastronikolis NS, Goumas P. Survival after laryngectomy: a review of 133 patients with laryngeal carcinoma. *Eur Arch Otorhinolaryngol* (2010) 267:1095–101. doi: 10.1007/s00405-009-1156-8

33. Leoncini E, Vukovic V, Cadoni G, Giraldi L, Pastorino R, Arzani D, et al. Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium. *Eur J Epidemiol* (2018) 33:1205–18. doi: 10.1007/s10654-018-0409-5

34. Fong PY, Tan SH, Lim DW, Tan EH, Ng QS, Sommat K, et al. Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). *PloS One* (2019) 14:e0224665. doi: 10.1371/journal.pone.0224665

35. Markou K, Goudakos J, Triaridis S, Konstantinidis J, Vital V, Nikolaou A. The role of tumor size and patient’s age as prognostic factors in laryngeal cancer. *Hippokratia* (2011) 15:75–80.

36. Bradford CR, Ferlito A, Devaney KO, Mäkitie AA, Rinaldo A. Prognostic factors in laryngeal squamous cell carcinoma. *Laryngoscope Investig Otolaryngol* (2020) 5:74–81. doi: 10.1002/lio2.353

37. Zhu X, Heng Y, Zhou L, Zhang M, Li W, Tao L. Survival prediction and treatment strategies for patients with advanced laryngeal carcinoma: a population-based study. *Int J Clin Oncol* (2020) 25(8):1483–91. doi: 10.1007/s10147-020-01688-9

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Zhang, Wang, Zhao, Zhang, Liu, Liu, Meng, Xin and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*